NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is Michelle and I will facilitate today ...

CEL-SCI Corporation today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in ...

At this time, I would like to welcome everyone to Karyopharm Therapeutics third quarter 2024 financial results conference ...

The combination therapy with checkpoint inhibitors makes sense ... Bria-OTS has been given different names depending on the type of cancer that is being targeted. Bria-BRES+, Bria-PROS+, Bria ...

The results nevertheless make Opdualag an alternative to Opdivo plus Yervoy (ipilimumab) – BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a ...

Inovio Pharmaceuticals ( INO -3.64%) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single phase 3 accelerated ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

A new analysis has revealed detailed 3D maps of the internal structures of multiple tumor types. These cancer atlases reveal how different tumor cells -- and the cells of a tumor's surrounding ...